| Abstracts |
| |
Article Title |
Author(s) |
Pages |
|
|
|
1 One Year Survival and Functional Status of Patients from the Human Ex Vivo Lung Perfusion (HELP) Trial
More than 80% of donor lungs are potentially injured and therefore not used for transplantation. A clinical trial using Normothermic Ex vivo Lung Perfusion (EVLP) to improve and re-assess lung functio...
|
M. Cypel,
M. Sato,
J.C. Yeung,
M. Liu,
M. Anraku,
S. Azad,
C.-W. Chow,
C. Chaparro,
M. Hutcheon,
L.G. Singer,
K. Yasufuku,
M. dePerrot,
A. Pierre,
T.K. Waddell,
S. Keshavjee
et al.
|
S8
|
|
|
|
2 Everolimus-Based Immunosuppression Versus Conventional Treatment in Long-Term Heart Transplanted Patients: Three Years Results of a Prospective Randomized Trial
CyA-based immunosuppression after Htx can result in worsening renal function and an elevated incidence of lymphomas. Whether changing from a CyA- to an Everolimus-based (EVL) immunosuppression in long...
|
R. Fiocchi,
R. Sebastiani,
E. Radavelli,
A. Gamba
|
S8
|
|
|
|
3 Combination Therapy with Pulsatile Left Ventricular Assist Device, Heart Failure Medication and Clenbuterol in Chronic Heart Failure: Results from HARPS
LVAD plus max med HF therapy followed by clenbuterol (CLEN) has resulted in high rates of ventricular recovery and LVAD explant with sustained survival in a single-center study of pts with acute and c...
|
K.D. Aaronson,
F.D. Pagani,
S.W. Maybaum,
D.S. Feldman,
R.C. Bogaev,
J.B. O'Connell,
S.W. Boyce,
E.W. McGee,
B.C. Sun,
D.J. Goldstein,
O.H. Frazier,
J.D. Myles,
K.J. Weatherwax,
L. Basobas,
L. McGowan,
D.J. Farrar,
M.H. Yacoub,
E.J. Birks,
L.W. Miller
et al.
|
S8-S9
|
|
|
|
4 National Trends in Readmission(REA) Rates Following Left Ventricular Assist Device (LVAD) Therapy
LVAD therapy has improved management and survival for end-stage CHF patients. The reasons for all cause hospital REA and frequency have not been reported to date outside of clinical trials. We report ...
|
P. Bonde,
M.A. Dew,
D. Meyer,
J.J. Tallaj,
T. Martin,
K.A. Hollifield,
M. Slaughter,
R. Starling,
R.L. Kormos
et al.
|
S9
|
|
|
|
5 Risk for Bleeding after MCSD Implant: An Analysis of 2358 Patients in INTERMACS
Bleeding remains a major complication after MCSD implant. Both device type and patient characteristics have been identified as risk factors for bleeding. The Interagency Registry for Mechanically Assi...
|
M.L. Jessup,
D. Goldstein,
D.D. Ascheim,
J.J. Teuteberg,
S.J. Park,
D.C. Naftel,
G.V. Gonzales-Stawirski,
K.L. Ulisney,
J.K. Kirklin,
R.L. Kormos
et al.
|
S9
|
|
|
|
6 Are Blood Stream Infections Associated with Increased Risk of Stroke in Patients with a Continuous Flow Left Ventricular Assist Device?
Blood stream infections (BSI) are an important source of morbidity and mortality in left ventricular assist device (LVAD) patients. The link between BSI and increased risk of stroke has been well esta...
|
J.A. Baumblatt,
S. Pauwaa,
A. Treitman,
C. Gallagher,
C. Blair,
P. Pappas,
A.J. Tatooles,
G. Bhat
et al.
|
S9-S10
|
|
|
|
7 Driveline Infections in LVADs: Is It the Pump or the Patient?
While LVAD support has become standard therapy for end stage heart disease, the complexities of device and patient management remain a concern. In particular, driveline infections (DLI) are a serious ...
|
D.J. Goldstein,
D.C. Naftel,
W.L. Holman,
L. Bellumkonda,
S.V. Pamboukian,
F.D. Pagani,
J.K. Kirklin
et al.
|
S10
|
|
|
|
8 Differential Infection Rates between Velour Versus Silicone Interface at the HeartMate II Driveline Exit Site: Structural and Ultrastructural Insight into Possible Causes
Prevention of driveline exit site (DLES) infection by attentive wound care is imperative but intrinsic differences in interface material may also influence infectious risk. In this study, we compare D...
|
I.D. Ledford,
D.V. Miller,
N.O. Mason,
R.A. Alharethi,
B.Y. Rasmusson,
D. Budge,
S.L. Stoker,
S.E. Clayson,
J.R. Doty,
G.E. Thomsen,
W.T. Caine,
A.G. Kfoury,
B.B. Reid
et al.
|
S10-S11
|
|
|
|
9 Hemolysis Predicts Poor Outcome Following LVAD Implant
To determine the clinical relevance of isolated serum markers of hemolysis during LVAD support.
|
M.A. Romano,
J.W. Haft,
J.M. Stulak,
K.D. Aaronson,
F.D. Pagani,
J. Cowger
et al.
|
S11
|
|
|
|
10 Can Soluble HLA-G Levels Predict the Development of Cardiac Allograft Vasculopathy?
Cardiac allograft vasculopathy (CAV) represents one of the major causes of morbidity and mortality post heart transplantation. Immune factors play an important role in its development and progression....
|
A.G. Mociornita,
J.M. Joseph,
V. Rao,
J. Sheedy,
H.J. Ross,
D.H. Delgado
et al.
|
S11
|
|
|
|
11 Coronary Angioplasty/Stents for Cardiac Allograft Vasculopathy Does Not Alter Outcome for Heart Transplant Patients with ISHLT CAV2 or CAV3 Disease
Percutaneous coronary intervention (PCI) with stents in cardiac allograft vasculopathy (CAV) is palliative but its impact on longterm outcome is not established. The new ISHLT CAV classification allow...
|
J. Patel,
B. Azarbal,
M. Kittleson,
M. Kawano,
Z. Goldstein,
M. Rafiei,
A. Moradzadeh,
L. Czer,
R. Kass,
J. Kobashigawa
et al.
|
S11-S12
|
|
|
|
12 Hyperlipidemia from Sirolimus: Adverse Impact on Development of Cardiac Allograft Vasculopathy
Sirolimus (SRL) has been shown to decrease the incidence of rejection and cardiac allograft vasculopathy (CAV). Yet SRL also causes dyslipidemia, primarily hypertriglyceridemia and an increase in LDL ...
|
J. Patel,
M. Kittleson,
M. Kawano,
Z. Goldstein,
M. Rafiei,
A. Moradzadeh,
B. Azarbal,
L. Czer,
R. Kass,
J. Kobashigawa
et al.
|
S12
|
|
|
|
13 Cardiac Allograft Hypertrophy Is Associated with Impaired Exercise Tolerance after Heart Transplantation
Exercise performance, an important aspect of quality of life, remains limited after heart transplantation (HTx). This prospective cross-sectional study examined the effect of early changes of cardiac ...
|
E. Raichlin,
M.A. Al-Omari,
S.S. Kushwaha,
B.S. Eswards,
A.L. Clavel,
R.J. Rodeheffer,
R.P. Frantz,
R.C. Daly,
S. Park,
T.G. Allison,
N.L. Pereira
et al.
|
S12
|
|
|
|
14 Heart-Lung Transplantation May Confer Protection from Developing Transplant Coronary Artery Disease: An Analysis of the United Organ Network Sharing Database
Previous studies suggested a protective effect of one organ on another in combined organ allografts with reduced rejection rates. Whether a similar protection is present for the development of transpl...
|
V.K. Topkara,
M. Yeung,
P.-H. Huang,
A.M. Hadi,
S.M. Joseph,
J.D. Schilling,
S.C. Sylvestry,
N. Moazami,
I.-W. Wang,
G.A. Ewald
et al.
|
S12-S13
|
|
|
|
15 Can Blood Biomarkers Improve the Assessment of Severity of Allograft Vasculopathy?
Long term survival of cardiac transplant (Tx) recipients is largely limited by the development of cardiac allograft vasculopathy (CAV). Currently, the diagnosis of CAV involves assessment of luminal s...
|
D. Lin,
G. Cohen Freue,
Z. Hollander,
A. Mui,
J. Wilson-McManus,
R. Balshaw,
R. Ng,
P. Keown,
R. McMaster,
B. McManus
et al.
|
S13
|
|
|
|
16 Right Ventricular-Pulmonary Arterial Coupling Is an Independent Predictor of Outcomes in Pulmonary Hypertension
Right ventricular (RV) dysfunction confers poor prognosis in pulmonary hypertension (PH). Predicting which patients will do poorly and when remains difficult. Hemodynamic calculations of RV-pulmonary ...
|
M.A. Simon,
V. Kosaraju,
C. Deible,
J. Lacomis,
C. Bunner,
M.A. Mathier,
H.C. Champion
et al.
|
S13
|
|
|
|
17 Prevalence and Predictors of Pulmonary Hypertension in End-Stage Chronic Obstructive Pulmonary Disease
Limited information is available regarding the prevalence of pulmonary hypertension (PH) diagnosed with right heart catheterization (RHC) in patients with end-stage chronic obstructive pulmonary disea...
|
K.H. Andersen,
M.P. Iversen,
J. Kjaergaard,
J. Mortensen,
E. Bendstrup,
R. Videbaek,
J. Carlsen
et al.
|
S13-S14
|
|
|
|
18 Does Geographic Distance From a Pulmonary Hypertension Center Delay Diagnosis and Treatment? A REVEAL Registry Analysis
Pulmonary arterial hypertension (PAH) patients in rural areas often travel long distances to PH centers. Preliminary data suggest that earlier diagnosis and earlier treatment initiation improves patie...
|
C.J. Markin,
L.L. Roessel,
G.P. Lai,
M. Turner,
R.J. Barst
et al.
|
S14
|
|
|
|
19 Utility of Changes in Heart Rate and Blood Pressure during Six Minute Walk Test as Predictors of Outcomes in Pulmonary Arterial Hypertension
While six minute walk distance (6MWD) remains the most utilized clinical endpoint in pulmonary arterial hypertension (PAH), no studies have attempted to use other relevant data captured during the tes...
|
S. Saito,
F. Haddad,
M. Skhiri,
A. Hsi,
E. Spiekerkoetter,
V. de Jesus Perez,
K. Kudelko,
R.T. Zamanian
et al.
|
S14
|
|
|
|
20 REVEAL: Syncope in Pulmonary Arterial Hypertension
We investigated the association of syncope with clinical and hemodynamic factors in patients with pulmonary arterial hypertension (PAH) enrolled in the Registry to EValuate Early And Long-term PAH Dis...
|
R. Le,
G.C. Kane,
R.P. Frantz,
H.W. Farber,
M. Turner,
R.J. Barst
et al.
|
S14-S15
|
|
|
|
21 Relaxin Levels Elevated in Patients with Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) results from the imbalance of various vasoactive mediators responsible for the vasoconstriction and proliferation of pulmonary arterial (PA) endothelial and smoot...
|
J.A. Mazurek,
M.R. Sardar,
W. Saeed,
R. Zolty
|
S15
|
|
|
|
22 The Real Potential of Donation after Cardiac Death (DCD) Lung Donors: Exploding the Myths
Donation after Cardiac Death (DCD) now represents an alternative source of donor lungs. However there are many myths and limited data regarding DCD donor lung availability, acceptability, referral-tra...
|
B.J. Levvey,
G.P. Westall,
H.M. Whitford,
T.C. Kotsimbos,
T.J. Williams,
G.I. Snell
et al.
|
S15
|
|
|
|
23 Effect of Donor Premortem Hypoxia and Hypotension on Graft Function and Start of Warm Ischemia in Donation after Cardiac Death Lung Transplantation
The start of warm ischemic time (WIT) of donor lungs in donation after cardiac death (DCD) is not clearly defined. We investigated the effect of donor premortem hypotension and hypoxia to determine wh...
|
K. Miyoshi,
T. Oto,
S. Otani,
S. Tanaka,
M. Harada,
T. Kakishita,
S. Hori,
S. Sugimoto,
M. Yamane,
S. Miyoshi
et al.
|
S15-S16
|
|
|
|
24 Transplantation of Lungs Recovered from Donors after Euthanasia
Donors after cardiac death (DCD) have increasingly supplied organs for lung transplantation (LTx). The use of lungs from donors after euthanasia has not yet been reported.
|
D. Van Raemdonck,
A. Neyrinck,
L. Dupont,
W. Coosemans,
H. Decaluwé,
P. De Leyn,
P. Nafteux,
G.M. Verleden
et al.
|
S16
|
|
|
|
25 Impact of the Lung Allocation Score (LAS) on Lung Transplant (LTX) in the US
The LAS, introduced in May 2005, changed lung allocation in the US for candidates 12 years and older, from allocating donor lungs to LTX candidates based on waiting time, to prioritizing candidates ba...
|
T.M. Egan,
L.B. Edwards
|
S16
|
|
|
|
26 Outcomes of Marginal Donors vs. Ideal Donors in Lung Transplantation by Donor Organ Score [DOS]
The demand for lung transplantation exceeds the supply of lung donations. Expansion of the acceptable criteria for donor selection-marginal donors has become a principle strategy worldwide.The purpose...
|
Y. Zemel,
B. Medalion,
Y. Raviv,
D. Rosengarten,
O. Fructer,
M. Saute,
I. Bakal,
M.R. Kramer
et al.
|
S16-S17
|
|
|
|
27 Predictive Algorithms for Matching Donor and Recipient Lung Size for Transplantation Using Three-Dimensional Computed Tomographic (3D CT) Volumetry
Donor and recipient size mismatching for lung transplantation can lead to serious complications. Although a few centers use predicted total lung capacity (pTLC), height is generally utilized for match...
|
Z.N. Kon,
J.A. Konheim,
C.S. White,
J.P. Garcia,
J. Jeudy,
B.P. Griffith
et al.
|
S17
|
|
|
|
28 Performance of Routine C4d and C3d Immunostaining on Protocol EMBs in a Prospective and Unselected Cohort of Heart Transplant Patients
In heart transplants, subclinical forms of antibody mediated rejection (AMR) are increasingly recognized in protocol EMBs as an emerging cause of late transplant failure. In this setting, the clinical...
|
A. Loupy,
A. Cazes,
R. Guillemain,
C. Suberbielle,
M. Tible,
C. Amrein,
V. Pezzella,
J.-N. Fabiani,
G.S. Hill,
D. Nochy,
P. Bruneval,
J.-P. Duong Van Huyen
et al.
|
S17
|
|
|
|
29 Inter-Observer Variation in Grading Capillary C4d Deposition in Cardiac Allograft Biopsies – A Single-Centre Study
Diagnosis of antibody mediated rejection (AMR) is based on clinical, serological and pathological data. The ISHLT Pathology Council is currently revising pathological criteria for AMR diagnosis, to in...
|
A. Rice,
B. Mitchelson,
W. Banya,
N. Banner,
M. Burke
et al.
|
S17
|
|
|
|
30 Does the Detection of Circulating Donor-Specific Antibody Impact Pathology Diagnosed Antibody-Mediated Rejection Outcome after Heart Transplant?
According to a recent consensus conference on antibody-mediated rejection (AMR), AMR should be defined solely by pathologic criteria. The presence of donor specific antibody (DSA) was not mandated in ...
|
M. Kittleson,
M. Kawano,
Z. Goldstein,
M. Rafiei,
B. Azarbal,
J. Moriguchi,
A. Hage,
N. Reinsmoen,
E. Reed,
D. Luthringer,
F. Esmailian,
J. Kobashigawa
et al.
|
S17-S18
|
|
|
|
31 Value of Immunoperoxidase Staining of C3d in the Diagnosis of Antibody Mediated Rejection in Heart Transplant Recipients
Nowadays C4d is an important criteria for diagnosing AMR. Few information are available on the role of C3d in the diagnosis of AMR. Aim of present study was to evaluate utility of C3d in identifying t...
|
M. Fedrigo,
A. Gambino,
E. Benazzi,
F. Poli,
A.C. Frigo,
F. Tona,
A. Caforio,
C. Castellani,
G. Toscano,
G. Feltrin,
G. Gerosa,
G. Thiene,
A. Angelini
et al.
|
S18
|
|
|
|
32 Microvessel Density in Cardiac Allograft Biopsies of Patients with Clinically Significant Coronary Allograft Vasculopathy
Cardiac Allograft Vasculopathy (CAV) remains the leading cause of late morbidity and mortality in heart transplant patients. Both immune-mediated and nonimmune factors influence CAV. Immunologic endot...
|
M.P. Revelo,
D. Budge,
D.V. Miller,
K.D. Brunisholz,
T.L. Bair,
M.E.H. Hammond,
G.L. Snow,
J. Stehlik,
E.M. Gilbert,
M.D. Everitt,
R.A. Alharethi,
A.G. Kfoury
et al.
|
S18
|
|
|
|
33 Serial Phenotyping Identifies Circulating B Cell Signatures within Six Months of Cardiac Transplantation
Recent histological and genoarray studies identified B cell signatures associated with renal transplant tolerance or chronic rejection. The role of B cells in cardiac rejection is poorly characterised...
|
E.L. Moseley,
M.J. Goddard,
A.R. Exley,
J. Wallwork,
C. Atkinson
et al.
|
S18-S19
|
|
|
|
34 Prediction of Weaning Success after Right Ventricular Assist Device Removal
Differences between right (RV) and left ventricular (LV) geometry, wall thickness, myofiber architecture, blood supply and load dependency of function, limit the use of experience obtained from LV stu...
|
M. Dandel,
E. Potapov,
A. Stepanenko,
T. Krabatsch,
T. Drews,
H.B. Lehmkuhl,
C. Knosalla,
R. Hetzer
et al.
|
S19
|
|
|
|
35 Predictors of Right Ventricular Assist Device Following Left Ventricular Assist Device Implantation: An Assessment of Scoring Systems
The development of right ventricular (RV) failure is a grave complication after placement of a left ventricular assist device (LVAD). Frequently, RVAD support is necessary. Numerous attempts to identi...
|
J.A. Yang,
E.Y. Chan,
B.P. Shulman,
M.S. Koekert,
D. Lumbao,
M.A. Lippel,
N. Uriel,
M. Argenziano,
U.P. Jorde,
Y. Naka,
H. Takayama
et al.
|
S19
|
|
|
|
36 Continuous Flow Ventricular Assist Devices Improve Functional Tricuspid Regurgitation and Right Ventricular Function
Continuous flow left ventricular assist devices (VAD) are being implanted with increasing frequency. At VAD implantation, the majority of patients have significant functional tricuspid regurgitation(T...
|
P. Atluri,
B.W. Ullery,
J.W. MacArthur,
E.D. Kozin,
W. Hiesinger,
J.P. Donnelly,
M.A. Acker,
J.E. Rame,
Y.J. Woo
et al.
|
S19-S20
|
|
|
|
37 Tricuspid Valve Insufficiency in Patients with Axial-flow Left Ventricular Assist Devices
The HeartMate II (HM II) continuous-flow left ventricular assist device (LVAD) has emerged as the standard of care for patients with advanced heart failure. The objective of this study was to assess t...
|
S. Maltais,
S.H. Mckellar,
T. Hasin,
Y. Topilsky,
R. Tsutsui,
L.D. Joyce,
R.C. Daly,
S.S. Kushwaha,
S.J. Park
et al.
|
S20
|
|
|
|
38 Biventricular Implantation of the HeartWare HVAD in an Animal Study
The rotary blood pump from HeartWare is an established left ventricular assist device. The special small design of the pump predestines this pump for a biventricular use. The use of flow restriction t...
|
A.L. Meyer,
M. Avsar,
W. Sommer,
D. Malehsa,
K. Dreckmann,
A. Haverich,
M. Strueber
et al.
|
S20
|
|
|
|
39 Predictability of Postoperative Right Ventricular Function before Left Ventricular Assist Device Implantation
Prolongation of waiting times for heart transplantation and growing numbers of non-transplantable patients with heart failure increase the need for mechanical cardiac support systems. Left ventricular...
|
M. Dandel,
A. Stepanenko,
E. Potapov,
T. Krabatsch,
C. Knosalla,
H.B. Lehmkuhl,
R. Hetzer
et al.
|
S20
|
|
|
|
40 A Longitudinal Study of the Course of Untreated Antibody-Mediated Rejection in Heart Transplantation
Growing evidence suggests worse cardiac allograft vasculopathy and mortality in heart transplant recipients with asymptomatic antibody-mediated rejection (AMR). It is being debated whether therapeutic...
|
A.G. Kfoury,
J.J. Connelly,
G.L. Snow,
D. Budge,
D.V. Miller,
F.M. Bader,
R.A. Alharethi,
J. Stehlik,
B.B. Reid,
M.D. Everitt,
M.P. Revelo,
E.M. Gilbert,
C.H. Selzman,
M.E.H. Hammond
et al.
|
S20-S21
|
|
|
|
41 The Effects of Moderate Strength Pre-Transplant Circulating Antibodies on Outcome after Heart Transplantation
Pre-transplant patients with high titers of donor-specific antibodies (DSA) are at risk for hyperacute rejection. The virtual cross match (VXM) reduces the risk of hyperacute rejection by determining ...
|
J. Patel,
M. Kittleson,
M. Kawano,
Z. Goldstein,
E. Stimpson,
J. Rush,
M. Rafiei,
N. Reinsmoen,
E. Reed,
M. Hamilton,
A. Trento,
J. Kobashigawa
et al.
|
S21
|
|
|
|
42 The Importance of Low-Titer Anti-HLA Antibodies in Cardiac Transplantation
Institution of flow cytometry based assays for detection and determination of specific anti-HLA antibodies to permit virtual crossmatching holds the promise of expanding the donor pool for heart trans...
|
G.F. Egnaczyk,
D.-F. Chen,
C.B. Patel,
K.R. White,
G.M. Felker,
P. Rosenberg,
A.F. Hernandez,
C.A. Milano,
J.G. Rogers
et al.
|
S21
|
|
|
|
43 Heart Transplantation in Sensitized Recipients, the Impact of Pre-Transplant Donor-Specific Antibodies on Clinical Outcome
We investigated the clinical outcomes in sensitized heart transplant recipients with and without anti-HLA donor-specific antibodies (DSA).
|
B. Sareyyupoglu,
Y. Toyoda,
K. Fujimoto,
J.J. Teuteberg,
M.A. Shullo,
D. Zaldonis,
P. Bonde,
J.K. Bhama,
C. Bermudez,
R.L. Kormos,
A. Zeevi
et al.
|
S21-S22
|
|
|
|
44 Timing of the Development of Donor Specific Antibody after Heart Transplantation Impacts Long-Term Outcome
The development of donor specific antibodies (DSA) after heart transplant (HT) negatively impacts long term outcomes. Whether early development of DSA (< 1 year post transplant) is worse than late ...
|
M. Kittleson,
J. Patel,
M. Kawano,
Z. Goldstein,
M. Rafiei,
N. Reinsmoen,
E. Reed,
A. Hage,
E. Schwarz,
F. Esmailian,
J. Kobashigawa
et al.
|
S22
|
|
|
|
45 Antibody-Mediated Rejection in Heart Transplantation: Clinical Follow-Up
C4d is widely accepted as a marker for antibody-mediated rejection in cardiac allografts. The aim of this prospective study was to determine the significance of C4d immunoreactivity in endomyocardial ...
|
S.E. Fedson,
M.K. Mizra,
Y. Chi,
A.N. Husain
|
S22
|
|
|
|
46 Temporal Trends in the Prevalence of Primary Graft Dysfunction after Lung Transplantation in the Lung Transplant Outcomes Group (LTOG) Cohort
The lung allocation system (LAS) in the US has led to the transplantation of more ill lung transplant candidates. We hypothesized that transplant recipients would have a higher risk of primary graft d...
|
H.Y. Robbins,
S.M. Arcasoy,
S. Bhorade,
M.M. Crespo,
S.M. Kawut,
V.N. Lama,
J.B. Orens,
S.M. Palmer,
P.D. Shah,
R. Shah,
J.R. Sonett,
L.B. Ware,
A. Weinacker,
K.M. Wille,
J.D. Christie,
D.J. Lederer
et al.
|
S22-S23
|
|
|
|
47 PTX3 Polymorphisms Are Associated with Primary Graft Dysfunction after Lung Transplantation
Primary graft dysfunction (PGD) is the leading cause of early post-transplant morbidity and mortality in lung transplant recipients. Abnormalities in innate immunity, mediated by long pentraxin-3 (PTX...
|
J.M. Diamond,
R. Feng,
N. Meyer,
D. Lederer,
J. Lee,
S. Kawut,
V. Ahya,
E. Cantu,
S. Palmer,
A. Weinacker,
S. Bhorade,
V. Lama,
J. Orens,
J. Sonett,
K. Wille,
M. Crespo,
D. Weill,
B. Kohl,
C. Deutschman,
S. Arcasoy,
A. Shah,
P.D. Shah,
E.J. Demissie,
J. Reynolds,
J. Belperio,
D. Wilkes,
L. Ware,
J.D. Christie
et al.
|
S23
|
|
|
|
48 Higher Plasma Leptin Levels Are Associated with Primary Graft Dysfunction after Lung Transplantation: The LTOG Obesity Study
There is an association between obesity and an increased risk of primary graft dysfunction (PGD) after lung transplantation. In this study, we hypothesized that higher plasma levels of leptin (a pro-i...
|
D.J. Lederer,
S.M. Kawut,
N. Wickersham,
C. Winterbottom,
J. Diamond,
S. Bhorade,
S. Palmer,
J. Lee,
K.M. Wille,
A. Weinacker,
V. Lama,
M. Crespo,
J. Orens,
S.M. Arcasoy,
L. Ware,
J.D. Christie
et al.
|
S23
|
|
|
|
49 Elevated PTX3 Concentration Is Associated with Primary Graft Dysfunction after Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis
Primary Graft Dysfunction (PGD) after lung transplantation is the result of ischemia-reperfusion (I-R) injury. Abnormal activation of innate immunity, in response to I-R injury, mediated by Toll-like ...
|
J.M. Diamond,
D. Lederer,
S.M. Kawut,
J. Lee,
E. Cantu,
V. Ahya,
S. Palmer,
A. Weinacker,
S. Bhorade,
V. Lama,
J.B. Orens,
J. Sonett,
K. Wille,
M. Crespo,
D. Weill,
B. Kohl,
C. Deutschman,
S. Arcasoy,
A. Shah,
P.D. Shah,
E.J. Demissie,
J.M. Reynolds,
J. Belperio,
D. Wilkes,
L. Ware,
J.D. Christie
et al.
|
S23-S24
|
|
|
|
50 VE-Cadherin Is Associated with Primary Graft Dysfunction in Lung Transplant Recipients
Primary graft dysfunction (PGD) causes significant morbidity and mortality in lung transplant (LTX) recipients; and therapeutic strategies are limited. VE-Cadherin is a member of the cadherin superfam...
|
S. Aharinejad,
M. Salama,
S. Taghavi,
M.A.R. Hoda,
W. Klepetko
et al.
|
S24
|
|
|
|
51 Revisiting the Diagnosis of Diffuse Alveolar Damage (DAD) after Lung Transplantation
Purpose: DAD is a non-specific histological pattern not infrequently encountered in transbronchial biopsies (TBBx) after lung transplantation (Tx). The purpose of the study is to examine the relations...
|
M. Sato,
T.K. Waddell,
D.M. Hwang,
C. Chaparro,
L.G. Singer,
M.A. Hutcheon,
S. Keshavjee
et al.
|
S24
|
|
|
|
52 Reduction of Cardiac Allograft Vasculopathy with Everolimus over Mycophenolate Mofetil: Intravascular Ultrasound Results of a Randomized Multicenter Trial
Cardiac allograft vasculopathy (CAV) is a major cause of long-term mortality following heart transplantation (HTx). In an earlier study, the mTOR inhibitor everolimus (EVR) was associated with lower i...
|
J. Kobashigawa,
D. Pauly,
H. Ross,
S. Wang,
B. Cantin,
J. Burton,
A. Keogh,
H. Eisen,
P. Lopez,
G. Dong,
H. Jiang,
M. Cines,
R. Starling
et al.
|
S24-S25
|
|
|
|
53 Everolimus Introduction and Calcineurin Reduction in Thoracic Transplant Recipients with Advanced Chronic Renal Failure
Purpose: The NOCTET (NOrdic Certican Trial in HEart and lung Transplantation) trial demonstrated that everolimus improves renal function in maintenance thoracic transplant recipients. Nevertheless, sw...
|
S. Arora,
B. Rundqvist,
S.-A. Mortensen,
H. Eiskjær,
G. Riise,
L. Mared,
O. Bjørtuft,
B. Ekmehag,
K. Jansson,
S. Simonsen,
E. Gude,
D. Solbu,
M. Iversen,
L. Gullestad
et al.
|
S25
|
|
|
|
54 Utilization of Sirolimus as Primary Immunosuppression Attenuates Cardiac Allograft Vasculopathy and Improves Late Survival in the Heart Transplant Population
Purpose: We investigated the potential of SRL as primary immunosuppressant in the long term attenuation of CAV progression and its effects on cardiac related morbidity and longer term survival. Method...
|
Y. Topilsky,
E. Raichlin,
B.A. Boilson,
J.A. Schirger,
N.L. Pereira,
B.S. Edwards,
A.L. Clavell,
R.J. Rodeheffer,
R.P. Frantz,
R.C. Daly,
A. Lerman,
S.S. Kushwaha
et al.
|
S25
|
|
|
|
55 Everolimus with Reduced CsA vs MMF with Standard CsA Exposure in De Novo Heart Transplant Recipients: 12 Month Efficacy and Safety Analysis
To show that everolimus (EVR; mTOR inhibitor) with reduced dose cyclosporine (CsA) achieves comparable efficacy and renal function (RF) to standard of care in de novo heart transplant recipients (HTxR...
|
H. Eisen,
D. Pauly,
R. Starling,
H. Lehmkuhl,
H. Ross,
A. Kfoury,
S. Wang,
B. Cantin,
A. Van Bakel,
A. Zuckermann,
P. Lopez,
G. Dong,
C. Panis,
H. Jiang,
C. Cornu-Artis,
J. Kobashigawa
et al.
|
S25-S26
|
|
|
|
56 Safety and Efficacy of Conversion to Sirolimus vs Continued Calcineurin Inhibitor Use in Cardiac Transplant Recipients with Renal Insufficiency
Evaluate the effect of conversion from a calcineurin inhibitor (CNI) to sirolimus (SRL) vs continued CNI use on renal function in cardiac transplant recipients with mild to moderate renal insufficienc...
|
A. Zuckermann,
A. Keogh,
M.G. Crespo-Leiro,
D. Mancini,
F. Gonzalez Vilchez,
L. Almenar,
H. Eisen,
S. See Tai,
S. Kushwaha
et al.
|
S26
|
|
|
|
57 Heart Transplant Recipients Treated with Everolimus Have Less Increase in Intimal Thickness vs MMF, Irrespective of Lipid Values
mTOR inhibition (mTORi) can reduce development of cardiac allograft vasculopathy (CAV), a major cause of long-term mortality in heart transplant recipients (HTxR). Hyperlipidemia, an mTORi side effect...
|
D. Pauly,
R. Starling,
J. Kobashigawa,
S. Wang,
B. Cantin,
A. Keogh,
H. Lehmkuhl,
S. Hirt,
P. Lopez,
G. Dong,
M. Cines,
H. Jiang,
H. Eisen
et al.
|
S26-S27
|
|
|
|
58 Sorting Out the Intricacies of Multiparity Risk on Outcomes after Heart Transplantation
Purpose: It has been demonstrated in the ISHLT registry that parous females have increased risk of rejection in the first year after heart transplant (HTx) vs. nulliparous females (JHLT 1997; 16(8):80...
|
E. Stimpson,
L. Piponniau,
J. Patel,
A. Velleca,
M. Kawano,
Z. Goldstein,
M. Rafiei,
N. Reinsmoen,
L. Czer,
F. Esmailian,
J. Kobashigawa
et al.
|
S27
|
|
|
|
59 Myth Buster: Does Homogeneous Racial Donor/Recipient Match Improve Outcome after Heart Transplantation?
Whether donor/recipient (D/R) race mismatch impacts long term outcome following heart transplant in patients on triple-drug immunosuppression is not clear. D/R race matching may result in less rejecti...
|
T. Kao,
A. Velleca,
M. Kittleson,
L. Piponniau,
J. Rush,
M. Kawano,
Z. Goldstein,
D. Luthringer,
L. Czer,
F. Esmailian,
J. Kobashigawa
et al.
|
S27
|
|
|
|
60 The Life of the Octogenarian Heart Transplant Patient
Heart transplantation is routinely performed for patients in their 60s and on select patients over 70. As these heart transplant patients survive into their 80's, octogenarian recipients now constitut...
|
D. Lockhart,
L. Piponniau,
A. Velleca,
J. Patel,
M. Kittleson,
B. Kearney,
T. Kao,
M. Johnson,
M. Kawano,
Z. Goldstein,
M. Rafiei,
J. Kobashigawa
et al.
|
S27-S28
|
|
